Navigation Links
Geranium extracts inhibit HIV-1
Date:1/30/2014

Scientists from the Helmholtz Zentrum Mnchen demonstrate that root extracts of the medicinal plant Pelargonium sidoides (PS) contain compounds that attack HIV-1 particles and prevent virus replication. A team spearheaded by Dr. Markus Helfer and Prof. Dr. Ruth Brack-Werner from the Institute of Virology and Prof. Dr. Philippe Schmitt-Kopplin from the Analytical BioGeoChemistry research unit (BGC) performed a detailed investigation of the effects of PS extracts on HIV-1 infection of cultured cells. They demonstrated that PS extracts protect blood and immune cells from infection by HIV-1, the most widespread type of HIV. PS extracts block attachment of virus particles to host cells and thus effectively prevent the virus from invading cells. Chemical analyses revealed that the antiviral effect of the PS extracts is mediated by polyphenols. Polyphenol mixtures isolated from PS extracts retain high anti-HIV-1 activity but are even less toxic for cells than the crude extract.

Safety of PS-extracts has been established in several clinical trials. In Germany PS extracts are licensed as a herbal medicine and used to reduce symptoms of acute bronchitis. Research group leader Brack-Werner says, "PS-extracts are a very promising lead for the development of the first scientifically validated phytomedicine against HIV-1. PS extracts attack HIV-1 with a mode-of-action that is different from all anti-HIV-1 drugs in clinical use. Therefore a PS-based phytomedicine may be a valuable supplement for established anti-HIV therapies. Furthermore, PS extracts are attractive candidates for increasing anti-HIV-1 therapy options in resource-limited settings, since they are easy to produce and do not require refrigeration. The results of our study and the proven safety of PS extracts encourages their testing in HIV-1 infected individuals as next step."

According to the World Health Organisation (WHO), more than 35 million people in the world are infected with HIV, the majority with HIV-1. Without treatment, HIV destroys the immune system and causes the acquired immunodeficiency syndrome (AIDS), which is a life-threatening disease. HIV/AIDS is one of the 10 leading causes of death worldwide.

The goal of research at the Helmholtz Zentrum Mnchen is to develop new approaches to diagnosing, treating and preventing common diseases. In the interest of translational research, the acquired knowledge is to be applied to humans as quickly as possible in order to provide concrete benefits for society.


'/>"/>
Contact: Ruth Brack-Werner
brack@helmholtz-muenchen.de
49-893-187-2923
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Source:Eurekalert

Related medicine news :

1. Dr. Oz Pure Garcinia Cambogia Extracts Now Offers Extra 3 Premium Bonuses to USA, UK, Australia and Canada
2. All-Natural Garcinia Cambogia Extracts Appetite Suppressant Now Offers 1 Extra Bottle with Every Purchase
3. Biostimulants Market (Humic Acid, Fulvic Acid, Amino Acid, Seaweed Extracts) Worth $2,241.0 Million by 2018 - New Report by MarketsandMarkets
4. Doctor Utilizes Stem Cell Extracts with Promising Results
5. Sodium Reduction Market by Ingredients (Amino Acids, Mineral Salts, Yeast Extracts) worth $1 Billion by 2018 - New Report by MarketsandMarkets
6. Wayne State part of team for license on new ways to manage cancer with green tea extracts
7. Specific inhibition of autophagy may represent a new concept for treatment of kidney cancer
8. Strategy discovered to activate genes that suppress tumors and inhibit cancer
9. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
10. VyGone Inhibitor Zapper: The Brand New Solution For the Safe Treatment Of Sores, Warts and Herpes
11. Inhibiting Hedgehog signaling pathway may improve pancreatic cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... and David Konur, CEO of Cardiovascular Institute of the South announced today that ... performing a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... performance in the industry’s gold standard KLAS Performance Report, Epic Consulting ... report assessed organizations that specialize in consulting services for electronic health record (EHR) ...
(Date:5/5/2016)... ... May 05, 2016 , ... Florida Hospital ... non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin medication with the newly ... in April of 2015, Florida Hospital Pepin Heart Institute doctors successfully implanted the ...
(Date:5/5/2016)... , ... May 05, 2016 ... ... hands-on exercises, the Wharton Seminars for Business Journalists , led by ... of key business and economic issues.  This one-day program at the Wharton ...
(Date:5/5/2016)... ... May 05, 2016 , ... An essential tool for researching ... certain Canadian provinces is now available from the International Association of Industrial Accident ... The report, Workers’ Compensation Laws as of January 1, 2016, is ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK ... technology, today announced Food and Drug Administration (FDA) ... defibrillator that provides heart failure patients with access ... devices also have remote monitoring with daily automatic ... the heart rate in response to physiological demands. ...
(Date:5/3/2016)... May 3, 2016   BIOTRONIK will be ... care beyond the implant at the Heart Rhythm Society,s ... San Francisco . ... highest quality of patient care and satisfaction possible. Part ... each and every tomorrow," said Marlou Janssen , ...
(Date:5/3/2016)... 3, 2016 Pharmaceutical giant Johnson ... to a woman who says its talc-based powder products ... Gloria Ristesund $5 million in compensatory damages and ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , This is ... company. In February, the same court awarded $72 million ...
Breaking Medicine Technology: